Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 4
2001 2
2002 7
2003 1
2004 6
2005 5
2006 2
2007 3
2008 4
2009 1
2010 2
2011 2
2012 2
2013 1
2014 4
2015 2
2016 1
2017 1
2018 4
2019 2
2020 3
2021 4
2022 5
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
Rivellese F, Surace AEA, Goldmann K, Sciacca E, Çubuk C, Giorli G, John CR, Nerviani A, Fossati-Jimack L, Thorborn G, Ahmed M, Prediletto E, Church SE, Hudson BM, Warren SE, McKeigue PM, Humby F, Bombardieri M, Barnes MR, Lewis MJ, Pitzalis C; R4RA collaborative group. Rivellese F, et al. Among authors: fossati jimack l. Nat Med. 2022 Jun;28(6):1256-1268. doi: 10.1038/s41591-022-01789-0. Epub 2022 May 19. Nat Med. 2022. PMID: 35589854 Free PMC article. Clinical Trial.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C; R4RA collaborative group. Humby F, et al. Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2. Lancet. 2021. PMID: 33485455 Free PMC article. Clinical Trial.
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
Cooles FAH, Tarn J, Lendrem DW, Naamane N, Lin CM, Millar B, Maney NJ, Anderson AE, Thalayasingam N, Diboll J, Bondet V, Duffy D, Barnes MR, Smith GR, Ng S, Watson D, Henkin R, Cope AP, Reynard LN, Pratt AG; RA-MAP Consortium; Isaacs JD. Cooles FAH, et al. Ann Rheum Dis. 2022 Jun 9;81(9):1214-23. doi: 10.1136/annrheumdis-2022-222370. Online ahead of print. Ann Rheum Dis. 2022. PMID: 35680389 Free PMC article.
The RA-MAP Consortium: a working model for academia-industry collaboration.
Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulz-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium. Cope AP, et al. Nat Rev Rheumatol. 2018 Jan;14(1):53-60. doi: 10.1038/nrrheum.2017.200. Epub 2017 Dec 7. Nat Rev Rheumatol. 2018. PMID: 29213124 Free PMC article. Review.
Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT.
Humby F, Durez P, Buch MH, Lewis MJ, Bombardieri M, John C, Rizvi H, Warren L, Peel J, Fossati-Jimack L, Hands RE, Giorli G, Rivellese F, Cañete JD, Taylor PC, Sasieni P, Fonseca JE, Choy E, Pitzalis C. Humby F, et al. Among authors: fossati jimack l. Southampton (UK): National Institute for Health and Care Research; 2022 Aug. Southampton (UK): National Institute for Health and Care Research; 2022 Aug. PMID: 36001738 Free Books & Documents. Review.
Lessons from BXSB and related mouse models.
Izui S, Ibnou-Zekri N, Fossati-Jimack L, Iwamoto M. Izui S, et al. Among authors: fossati jimack l. Int Rev Immunol. 2000;19(4-5):447-72. doi: 10.3109/08830180009055507. Int Rev Immunol. 2000. PMID: 11016427 Review.
C3 Drives Inflammatory Skin Carcinogenesis Independently of C5.
Jackson WD, Gulino A, Fossati-Jimack L, Castro Seoane R, Tian K, Best K, Köhl J, Belmonte B, Strid J, Botto M. Jackson WD, et al. Among authors: fossati jimack l. J Invest Dermatol. 2021 Feb;141(2):404-414.e6. doi: 10.1016/j.jid.2020.06.025. Epub 2020 Jul 16. J Invest Dermatol. 2021. PMID: 32682912 Free PMC article.
Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS).
Pontarini E, Sciacca E, Chowdhury F, Grigoriadou S, Rivellese F, Murray-Brown WJ, Lucchesi D, Fossati-Jimack L, Nerviani A, Jaworska E, Ghirardi GM, Giacomassi C, Emery P, Ng WF, Sutcliffe N, Everett C, Fernandez C, Tappuni A, Seror R, Mariette X, Porcher R, Cavallaro G, Pulvirenti A, Verstappen GM, de Wolff L, Arends S, Bootsma H, Lewis MJ, Pitzalis C, Bowman SJ, Bombardieri M; Trial for Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome Study Research Group. Pontarini E, et al. Among authors: fossati jimack l. Arthritis Rheumatol. 2024 May;76(5):763-776. doi: 10.1002/art.42772. Epub 2024 Feb 15. Arthritis Rheumatol. 2024. PMID: 38073013 Clinical Trial.
65 results